{"transactions":[{"id":3517314,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-09-08T20:13:46.000Z","date":"2026-09-08","kind":"sale","planned":true,"acquired":false,"shares":5658,"price":18.88,"value":106823.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.77 to $18.92, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 239,233 unvested RSUs."}],"balance_after":357507,"source":{"system":"sec-edgar","filing":"0001498428-26-000005","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000149842826000005/ownership.xml","form_type":"4"}},{"id":685625,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-08-17T20:07:22.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":4986,"price":26.28,"value":131032.08,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $26.17 to $26.39, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 248,314 unvested RSUs."}],"balance_after":363165,"source":{"system":"sec-edgar","filing":"0001498428-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000149842826000004/ownership.xml","form_type":"4"}},{"id":734254,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-06-17T20:07:11.000Z","date":"2026-06-16","kind":"sale","planned":true,"acquired":false,"shares":2683,"price":18.33,"value":49179.39,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.00 to $18.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 259,564 unvested RSUs."}],"balance_after":368151,"source":{"system":"sec-edgar","filing":"0001498428-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000149842826000002/ownership.xml","form_type":"4"}},{"id":779356,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-05-14T20:02:42.000Z","date":"2026-05-13","kind":"sale","planned":true,"acquired":false,"shares":3311,"price":18.36,"value":60789.96,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on February 12, 2026. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $18.20 to $18.41, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 268,645 unvested RSUs."}],"balance_after":370834,"source":{"system":"sec-edgar","filing":"0001193125-26-223955","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526223955/ownership.xml","form_type":"4"}},{"id":856009,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-03-06T21:08:22.000Z","date":"2026-03-05","kind":"sale","planned":true,"acquired":false,"shares":2732,"price":14.9,"value":40706.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 279,895 unvested RSUs."}],"balance_after":374145,"source":{"system":"sec-edgar","filing":"0001193125-26-096512","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526096512/ownership.xml","form_type":"4"}},{"id":901192,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock option (right to buy)","published_at":"2026-02-17T22:11:53.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":285000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on February 12, 2026. The shares underlying the option are scheduled to vest over four years in equal monthly installments through February 12, 2030."}],"balance_after":285000,"derivative":{"exercise_price":16,"expiration_date":"2036-02-11","underlying":"Common Stock","underlying_shares":285000},"source":{"system":"sec-edgar","filing":"0001193125-26-055075","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526055075/ownership.xml","form_type":"4"}},{"id":901191,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-02-17T22:11:53.000Z","date":"2026-02-12","kind":"grant","planned":false,"acquired":true,"shares":180000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 180,000 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on May 12, 2026."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 288,976 unvested RSUs."}],"balance_after":376877,"source":{"system":"sec-edgar","filing":"0001193125-26-055075","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312526055075/ownership.xml","form_type":"4"}},{"id":979156,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2025-12-05T21:11:49.000Z","date":"2025-12-05","kind":"sale","planned":true,"acquired":false,"shares":2662,"price":20.72,"value":55156.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Reporting Person's sale of shares of Common Stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), to the extent of 2,662 shares, with the Reporting Person's purchase of 100,000 shares on July 14, 2025. The Reporting Person has paid to the Issuer an aggregate amount of $31,111.88, representing the amount of the profit deemed realized in connection with the short-swing transaction under Section 16(b) of the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $20.58 to $20.96, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Includes 108,976 unvested RSUs."}],"balance_after":196877,"source":{"system":"sec-edgar","filing":"0001193125-25-309666","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000119312525309666/ownership.xml","form_type":"4"}},{"id":1044890,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2025-09-09T20:31:26.000Z","date":"2025-09-05","kind":"sale","planned":true,"acquired":false,"shares":2640,"price":13.41,"value":35402.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The Reporting Person's sale of shares of Common Stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), to the extent of 2,640 shares, with the Reporting Person's purchase of 100,000 shares on July 14, 2025. The Reporting Person has paid to the Issuer an aggregate amount of $11,565.07, representing the amount of the profit deemed realized in connection with the short-swing transaction under Section 16(b) of the Exchange Act."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 118,057 unvested RSUs."}],"balance_after":199539,"source":{"system":"sec-edgar","filing":"0001498428-25-000003","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000149842825000003/ownership.xml","form_type":"4"}},{"id":1084759,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock option (right to buy)","published_at":"2025-07-18T21:19:53.000Z","date":"2025-07-16","kind":"grant","planned":false,"acquired":true,"shares":197285,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on July 16, 2025 (the \"Grant Date\"). The shares underlying the option are scheduled to vest over three years, with 50% of the shares underlying the grant vesting 18 months after the Grant Date and with the balance of the shares underlying the grant vesting in equal quarterly installments thereafter; provided that such option shall not be exercisable unless and until (i) the average closing price of the common stock on the Nasdaq Global Select Market over a 20 consecutive trading day period equals or exceeds $20.00 per share at any time during the three-year period following the Grant Date (the \"Performance Period\") or (ii) a Change in Control (as defined in the Issuer's Amended and Restated Executive Severance and Change in Control Benefits Plan) is consummated during the Performance Period pursuant to which a third party acquires the common stock for a price per share that the Board of Directors of the Issuer determines equals or exceeds $20.00 per share."}],"balance_after":197285,"derivative":{"exercise_price":9.33,"expiration_date":"2035-07-15","underlying":"Common Stock","underlying_shares":197285},"source":{"system":"sec-edgar","filing":"0000950170-25-097005","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017025097005/ownership.xml","form_type":"4"}},{"id":1087387,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2025-07-15T21:11:40.000Z","date":"2025-07-15","kind":"gift","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This transaction represents a gift by the Reporting Person to a trust established for the benefit of a child of the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F5","text":"Includes 127,138 unvested RSUs."}],"balance_after":202179,"source":{"system":"sec-edgar","filing":"0000950170-25-095929","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017025095929/ownership.xml","form_type":"4"}},{"id":1087386,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2025-07-15T21:11:40.000Z","date":"2025-07-15","kind":"gift","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This transaction represents a gift by the Reporting Person to a trust established for the benefit of a child of the Reporting Person."}],"balance_after":212179,"source":{"system":"sec-edgar","filing":"0000950170-25-095929","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017025095929/ownership.xml","form_type":"4"}},{"id":1087385,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2025-07-15T21:11:40.000Z","date":"2025-07-15","kind":"gift","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This transaction represents a gift by the Reporting Person to a trust established for the benefit of a child of the Reporting Person."}],"balance_after":222179,"source":{"system":"sec-edgar","filing":"0000950170-25-095929","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017025095929/ownership.xml","form_type":"4"}},{"id":1087384,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2025-07-15T21:11:40.000Z","date":"2025-07-15","kind":"gift","planned":false,"acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This transaction represents a gift by the Reporting Person to a trust established for the benefit of a child of the Reporting Person."}],"balance_after":232179,"source":{"system":"sec-edgar","filing":"0000950170-25-095929","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017025095929/ownership.xml","form_type":"4"}},{"id":1087383,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2025-07-15T21:11:40.000Z","date":"2025-07-14","kind":"purchase","planned":false,"acquired":true,"shares":100000,"price":9.11,"value":911000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The Reporting Person's purchase of shares of Common Stock reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), to the extent of 8,121 shares, with the Reporting Person's sale of 4,061 shares on March 5, 2025 and 4,060 shares on June 5, 2025 automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The Reporting Person has paid to the Issuer an aggregate amount of $29,017.22, representing the amount of the profit deemed realized in connection with the short-swing transaction under Section 16(b) of the Exchange Act."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices within the range of $9.02 to $9.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."}],"balance_after":242179,"source":{"system":"sec-edgar","filing":"0000950170-25-095929","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017025095929/ownership.xml","form_type":"4"}},{"id":1119855,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2025-06-06T20:07:07.000Z","date":"2025-06-05","kind":"sale","planned":true,"acquired":false,"shares":4060,"price":13.35,"value":54201.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $13.21 to $13.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 127,138 unvested RSUs."}],"balance_after":142179,"source":{"system":"sec-edgar","filing":"0000950170-25-083071","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017025083071/ownership.xml","form_type":"4"}},{"id":1217568,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2025-03-07T21:07:03.000Z","date":"2025-03-05","kind":"sale","planned":true,"acquired":false,"shares":4061,"price":11.83,"value":48041.63,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of restricted stock units granted to the Reporting Person on December 4, 2024. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a \"binding contract\" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices within the range of $11.73 to $11.94, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote of this Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 136,219 unvested RSUs."}],"balance_after":146239,"source":{"system":"sec-edgar","filing":"0000950170-25-035495","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017025035495/ownership.xml","form_type":"4"}},{"id":1340568,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock option (right to buy)","published_at":"2024-12-06T21:05:09.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":232100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option was granted on December 4, 2024. The shares underlying the option are scheduled to vest over four years in equal monthly installments through December 4, 2028."}],"balance_after":232100,"derivative":{"exercise_price":29.44,"expiration_date":"2034-12-03","underlying":"Common Stock","underlying_shares":232100},"source":{"system":"sec-edgar","filing":"0000950170-24-134072","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024134072/ownership.xml","form_type":"4"}},{"id":1340567,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2024-12-06T21:05:09.000Z","date":"2024-12-04","kind":"grant","planned":false,"acquired":true,"shares":145300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of Common Stock issuable under 145,300 restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of Common Stock upon vesting. These RSUs are scheduled to vest in equal quarterly installments over four years with the first installment vesting on March 4, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 145,300 unvested RSUs."}],"balance_after":150300,"source":{"system":"sec-edgar","filing":"0000950170-24-134072","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024134072/ownership.xml","form_type":"4"}},{"id":1415920,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2024-09-04T21:42:18.000Z","date":"2024-09-04","kind":"purchase","planned":false,"acquired":true,"shares":7200,"price":33.09,"value":238248.0,"ownership":{"direct":false,"nature":"By Trust #4"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices within the range of $32.60 to $33.58, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held in a trust for the benefit of a child of the Reporting Person."}],"balance_after":8000,"source":{"system":"sec-edgar","filing":"0000950170-24-103533","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024103533/ownership.xml","form_type":"4"}},{"id":1415919,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2024-09-04T21:42:18.000Z","date":"2024-09-04","kind":"purchase","planned":false,"acquired":true,"shares":800,"price":32.57,"value":26056.0,"ownership":{"direct":false,"nature":"By Trust #4"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices within the range of $32.55 to $32.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held in a trust for the benefit of a child of the Reporting Person."}],"balance_after":800,"source":{"system":"sec-edgar","filing":"0000950170-24-103533","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024103533/ownership.xml","form_type":"4"}},{"id":1415918,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2024-09-04T21:42:18.000Z","date":"2024-09-04","kind":"purchase","planned":false,"acquired":true,"shares":7200,"price":33.09,"value":238248.0,"ownership":{"direct":false,"nature":"By Trust #3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices within the range of $32.60 to $33.58, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held in a trust for the benefit of a child of the Reporting Person."}],"balance_after":8000,"source":{"system":"sec-edgar","filing":"0000950170-24-103533","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024103533/ownership.xml","form_type":"4"}},{"id":1415917,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2024-09-04T21:42:18.000Z","date":"2024-09-04","kind":"purchase","planned":false,"acquired":true,"shares":800,"price":32.57,"value":26056.0,"ownership":{"direct":false,"nature":"By Trust #3"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices within the range of $32.55 to $32.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held in a trust for the benefit of a child of the Reporting Person."}],"balance_after":800,"source":{"system":"sec-edgar","filing":"0000950170-24-103533","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024103533/ownership.xml","form_type":"4"}},{"id":1415916,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2024-09-04T21:42:18.000Z","date":"2024-09-04","kind":"purchase","planned":false,"acquired":true,"shares":7200,"price":33.09,"value":238248.0,"ownership":{"direct":false,"nature":"By Trust #2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices within the range of $32.60 to $33.58, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held in a trust for the benefit of a child of the Reporting Person."}],"balance_after":8000,"source":{"system":"sec-edgar","filing":"0000950170-24-103533","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024103533/ownership.xml","form_type":"4"}},{"id":1415915,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2024-09-04T21:42:18.000Z","date":"2024-09-04","kind":"purchase","planned":false,"acquired":true,"shares":800,"price":32.57,"value":26056.0,"ownership":{"direct":false,"nature":"By Trust #2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices within the range of $32.55 to $32.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held in a trust for the benefit of a child of the Reporting Person."}],"balance_after":800,"source":{"system":"sec-edgar","filing":"0000950170-24-103533","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024103533/ownership.xml","form_type":"4"}},{"id":1415914,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2024-09-04T21:42:18.000Z","date":"2024-09-04","kind":"purchase","planned":false,"acquired":true,"shares":7200,"price":33.09,"value":238248.0,"ownership":{"direct":false,"nature":"By Trust #1"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices within the range of $32.60 to $33.58, inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held in a trust for the benefit of a child of the Reporting Person."}],"balance_after":8000,"source":{"system":"sec-edgar","filing":"0000950170-24-103533","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024103533/ownership.xml","form_type":"4"}},{"id":1415913,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2024-09-04T21:42:18.000Z","date":"2024-09-04","kind":"purchase","planned":false,"acquired":true,"shares":800,"price":32.57,"value":26056.0,"ownership":{"direct":false,"nature":"By Trust #1"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices within the range of $32.55 to $32.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range(s) set forth in the footnotes of this Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"These shares are held in a trust for the benefit of a child of the Reporting Person."}],"balance_after":800,"source":{"system":"sec-edgar","filing":"0000950170-24-103533","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024103533/ownership.xml","form_type":"4"}},{"id":1559596,"issuer":{"id":3948,"kind":"organization","name":"Dyne Therapeutics, Inc.","symbol":"DYN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-03-27T20:24:10.000Z","date":"2024-03-25","kind":"grant","planned":false,"acquired":true,"shares":679853,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on March 25, 2024. The shares underlying the option are scheduled to vest over four years, with 25% of the shares vesting on March 25, 2025, and the remainder vesting in equal monthly installments thereafter, subject to continuous service"}],"balance_after":679853,"derivative":{"exercise_price":26.06,"expiration_date":"2034-03-24","underlying":"Common Stock","underlying_shares":679853},"source":{"system":"sec-edgar","filing":"0000950170-24-037226","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1818794/000095017024037226/ownership.xml","form_type":"4"}},{"id":1809901,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T20:10:27.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":683,"price":4.9984,"value":3413.9072,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the \"Reverse Split\") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one CVR per Share subject to such stock option immediately prior to the Acceptance Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one CVR per Share subject to such stock option immediately prior to the Acceptance Time."}],"balance_after":0,"derivative":{"exercise_price":9.9216,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":683},"source":{"system":"sec-edgar","filing":"0001415889-23-012134","document":"form4-08112023_040818.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000141588923012134/form4-08112023_040818.xml","form_type":"4"}},{"id":1809900,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-11T20:10:27.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":683,"price":6.6439,"value":4537.7837,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the \"Reverse Split\") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one CVR per Share subject to such stock option immediately prior to the Acceptance Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, these stock options were cancelled and the Reporting Person was entitled to receive (without interest) (x) an amount in cash (less applicable Tax withholdings) equal to the product of (A) the total number of Shares subject to such option immediately prior to the Acceptance Time multiplied by (B) the excess, if any, of the Closing Amount over the applicable exercise price per Share under such option and (y) one CVR per Share subject to such stock option immediately prior to the Acceptance Time."}],"balance_after":0,"derivative":{"exercise_price":8.2761,"expiration_date":"2033-05-18","underlying":"Common Stock","underlying_shares":683},"source":{"system":"sec-edgar","filing":"0001415889-23-012134","document":"form4-08112023_040818.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000141588923012134/form4-08112023_040818.xml","form_type":"4"}},{"id":1809899,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-08-11T20:10:27.000Z","date":"2023-08-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":341,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive consideration per share of (i) $14.92, net to the stockholder in cash, without interest plus (ii) one Contingent Value Right (\"CVR\") per share"},{"field":"shares","element":"transactionShares","label":"F2","text":"Effective May 22, 2023, the Issuer effected a 1-for-13 reverse stock split (the \"Reverse Split\") of its issued and outstanding shares of Common Stock. Cash was paid in lieu of any fractional shares resulting from the Reverse Split. The Reporting Person's beneficial ownership in this Form 4 has been adjusted for the Reverse Split."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the Merger Agreement, as of the Effective Time, these shares were converted into the right to receive consideration per share of (i) $14.92, net to the stockholder in cash, without interest plus (ii) one Contingent Value Right (\"CVR\") per share"}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001415889-23-012134","document":"form4-08112023_040818.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000141588923012134/form4-08112023_040818.xml","form_type":"4"}},{"id":1882595,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-22T20:20:21.000Z","date":"2023-05-19","kind":"grant","planned":false,"acquired":true,"shares":8888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on May 19, 2024"}],"balance_after":8888,"derivative":{"exercise_price":0.6366,"expiration_date":"2033-05-18","underlying":"Common Stock","underlying_shares":8888},"source":{"system":"sec-edgar","filing":"0001415889-23-008494","document":"form4-05222023_040509.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000141588923008494/form4-05222023_040509.xml","form_type":"4"}},{"id":2253384,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-27T21:00:45.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":8888,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on May 26, 2023."}],"balance_after":8888,"derivative":{"exercise_price":0.7632,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":8888},"source":{"system":"sec-edgar","filing":"0001415889-22-005827","document":"form4-05272022_050513.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000141588922005827/form4-05272022_050513.xml","form_type":"4"}},{"id":2653433,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-28T11:15:22.000Z","date":"2021-06-24","kind":"grant","acquired":true,"shares":8888,"price":9.97,"value":88613.36,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was issued pursuant to the Sigilon Therapeutics, Inc. 2020 Equity Incentive Plan. The option will vest as to 100% on June 24, 2022."}],"balance_after":8888,"derivative":{"exercise_price":9.97,"expiration_date":"2031-06-23","underlying":"Common Stock","underlying_shares":8888},"source":{"system":"sec-edgar","filing":"0001415889-21-003238","document":"form4-06282021_070607.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000141588921003238/form4-06282021_070607.xml","form_type":"4"}},{"id":2950153,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Series B-1 Convertible Preferred Stock","published_at":"2020-12-10T23:15:59.000Z","date":"2020-12-08","kind":"exercise","acquired":false,"shares":4444,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock without payment or further consideration. There was no expiration date for the Series B-1 Convertible Preferred Stock."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock without payment or further consideration. There was no expiration date for the Series B-1 Convertible Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock without payment or further consideration. There was no expiration date for the Series B-1 Convertible Preferred Stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock without payment or further consideration. There was no expiration date for the Series B-1 Convertible Preferred Stock."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock without payment or further consideration. There was no expiration date for the Series B-1 Convertible Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by The John Gilbert Cox Living Trust dated 6/23/2006, as amended, of which the Reporting Person is the trustee."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4444},"source":{"system":"sec-edgar","filing":"0001104659-20-134300","document":"tm2037869-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000110465920134300/tm2037869-2_4seq1.xml","form_type":"4"}},{"id":2950152,"issuer":{"id":11481,"kind":"organization","name":"Sigilon Therapeutics, Inc.","symbol":"SGTX"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-12-10T23:15:59.000Z","date":"2020-12-08","kind":"exercise","acquired":true,"shares":4444,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock without payment or further consideration. There was no expiration date for the Series B-1 Convertible Preferred Stock."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Upon closing of the Issuer's initial public offering, each share of Series B-1 Convertible Preferred Stock automatically converted into shares of the Issuer's Common Stock without payment or further consideration. There was no expiration date for the Series B-1 Convertible Preferred Stock."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Held by The John Gilbert Cox Living Trust dated 6/23/2006, as amended, of which the Reporting Person is the trustee."}],"balance_after":4444,"source":{"system":"sec-edgar","filing":"0001104659-20-134300","document":"tm2037869-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000110465920134300/tm2037869-2_4seq1.xml","form_type":"4"}},{"id":3194832,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-26T23:31:58.000Z","date":"2020-03-24","kind":"sale","acquired":false,"shares":1858,"price":96.72,"value":179705.76,"ownership":{"direct":true},"balance_after":923,"source":{"system":"sec-edgar","filing":"0000899243-20-009592","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/730272/000089924320009592/doc4.xml","form_type":"4"}},{"id":3200042,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-20T20:25:46.000Z","date":"2020-03-18","kind":"exercise","acquired":false,"shares":3304,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":42.07,"expiration_date":"2028-05-16","underlying":"Common Stock","underlying_shares":3304},"source":{"system":"sec-edgar","filing":"0000899243-20-009121","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/730272/000089924320009121/doc4.xml","form_type":"4"}},{"id":3200041,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-20T20:25:46.000Z","date":"2020-03-18","kind":"exercise","acquired":false,"shares":2434,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":38.76,"expiration_date":"2027-05-18","underlying":"Common Stock","underlying_shares":2434},"source":{"system":"sec-edgar","filing":"0000899243-20-009121","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/730272/000089924320009121/doc4.xml","form_type":"4"}},{"id":3200040,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-20T20:25:46.000Z","date":"2020-03-18","kind":"exercise","acquired":false,"shares":3366,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":26.12,"expiration_date":"2026-05-11","underlying":"Common Stock","underlying_shares":3366},"source":{"system":"sec-edgar","filing":"0000899243-20-009121","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/730272/000089924320009121/doc4.xml","form_type":"4"}},{"id":3200039,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-20T20:25:46.000Z","date":"2020-03-18","kind":"exercise","acquired":false,"shares":3632,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":41.19,"expiration_date":"2025-05-21","underlying":"Common Stock","underlying_shares":3632},"source":{"system":"sec-edgar","filing":"0000899243-20-009121","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/730272/000089924320009121/doc4.xml","form_type":"4"}},{"id":3200038,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-20T20:25:46.000Z","date":"2020-03-18","kind":"exercise","acquired":false,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option is currently exercisable."}],"balance_after":0,"derivative":{"exercise_price":12.91,"expiration_date":"2023-11-15","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0000899243-20-009121","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/730272/000089924320009121/doc4.xml","form_type":"4"}},{"id":3200037,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-20T20:25:46.000Z","date":"2020-03-18","kind":"sale","acquired":false,"shares":1016,"price":97.17,"value":98724.72,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"$97.17 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $97.08 to $97.31, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":2781,"source":{"system":"sec-edgar","filing":"0000899243-20-009121","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/730272/000089924320009121/doc4.xml","form_type":"4"}},{"id":3200036,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-20T20:25:46.000Z","date":"2020-03-18","kind":"sale","acquired":false,"shares":1187,"price":96.45,"value":114486.15,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"$96.45 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $96.00 to $96.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":3797,"source":{"system":"sec-edgar","filing":"0000899243-20-009121","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/730272/000089924320009121/doc4.xml","form_type":"4"}},{"id":3200035,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-20T20:25:46.000Z","date":"2020-03-18","kind":"sale","acquired":false,"shares":24533,"price":95.13,"value":2333824.29,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"$95.13 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $95.00 to $95.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":4984,"source":{"system":"sec-edgar","filing":"0000899243-20-009121","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/730272/000089924320009121/doc4.xml","form_type":"4"}},{"id":3200034,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-20T20:25:46.000Z","date":"2020-03-18","kind":"exercise","acquired":true,"shares":3304,"price":42.07,"value":138999.28,"ownership":{"direct":true},"balance_after":29517,"source":{"system":"sec-edgar","filing":"0000899243-20-009121","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/730272/000089924320009121/doc4.xml","form_type":"4"}},{"id":3200033,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-20T20:25:46.000Z","date":"2020-03-18","kind":"exercise","acquired":true,"shares":2434,"price":38.76,"value":94341.84,"ownership":{"direct":true},"balance_after":26213,"source":{"system":"sec-edgar","filing":"0000899243-20-009121","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/730272/000089924320009121/doc4.xml","form_type":"4"}},{"id":3200032,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-20T20:25:46.000Z","date":"2020-03-18","kind":"exercise","acquired":true,"shares":3366,"price":26.12,"value":87919.92,"ownership":{"direct":true},"balance_after":23779,"source":{"system":"sec-edgar","filing":"0000899243-20-009121","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/730272/000089924320009121/doc4.xml","form_type":"4"}},{"id":3200031,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-20T20:25:46.000Z","date":"2020-03-18","kind":"exercise","acquired":true,"shares":3632,"price":41.19,"value":149602.08,"ownership":{"direct":true},"balance_after":20413,"source":{"system":"sec-edgar","filing":"0000899243-20-009121","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/730272/000089924320009121/doc4.xml","form_type":"4"}},{"id":3200030,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-20T20:25:46.000Z","date":"2020-03-18","kind":"exercise","acquired":true,"shares":14000,"price":12.91,"value":180740.0,"ownership":{"direct":true},"balance_after":16781,"source":{"system":"sec-edgar","filing":"0000899243-20-009121","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/730272/000089924320009121/doc4.xml","form_type":"4"}},{"id":3225816,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-03-05T22:52:06.000Z","date":"2020-03-04","kind":"exercise","acquired":false,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is currently exercisable."}],"balance_after":14000,"derivative":{"exercise_price":12.91,"expiration_date":"2023-11-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0000899243-20-007240","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/730272/000089924320007240/doc4.xml","form_type":"4"}},{"id":3225815,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-05T22:52:06.000Z","date":"2020-03-04","kind":"sale","acquired":false,"shares":10000,"price":93.39,"value":933900.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"$93.39 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $93.30 to $93.44, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":2781,"source":{"system":"sec-edgar","filing":"0000899243-20-007240","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/730272/000089924320007240/doc4.xml","form_type":"4"}},{"id":3225814,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-03-05T22:52:06.000Z","date":"2020-03-04","kind":"exercise","acquired":true,"shares":10000,"price":12.91,"value":129100.0,"ownership":{"direct":true},"balance_after":12781,"source":{"system":"sec-edgar","filing":"0000899243-20-007240","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/730272/000089924320007240/doc4.xml","form_type":"4"}},{"id":3247783,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-26T21:27:48.000Z","date":"2020-02-24","kind":"sale","acquired":false,"shares":4355,"price":92.76,"value":403969.8,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"$92.76 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $92.75 to $92.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range."}],"balance_after":2781,"source":{"system":"sec-edgar","filing":"0000899243-20-005905","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/730272/000089924320005905/doc4.xml","form_type":"4"}},{"id":3247782,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-26T21:27:48.000Z","date":"2020-02-24","kind":"sale","acquired":false,"shares":100,"price":94.85,"value":9485.0,"ownership":{"direct":true},"balance_after":7136,"source":{"system":"sec-edgar","filing":"0000899243-20-005905","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/730272/000089924320005905/doc4.xml","form_type":"4"}},{"id":3522828,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-17T20:11:51.000Z","date":"2019-05-15","kind":"grant","acquired":true,"shares":2109,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Award vests in full one year from grant date on May 15, 2020."}],"balance_after":2109,"derivative":{"exercise_price":67.71,"exercise_date":"2020-05-15","expiration_date":"2029-05-15","underlying":"Common Stock","underlying_shares":2109},"source":{"system":"sec-edgar","filing":"0000899243-19-013994","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/730272/000089924319013994/doc4.xml","form_type":"4"}},{"id":3522827,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-17T20:11:51.000Z","date":"2019-05-15","kind":"grant","acquired":true,"shares":923,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Mr. Cox was awarded 923 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The restricted stock units vest on May 15, 2020. The restricted stock units may be settled only be delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance."}],"balance_after":7236,"source":{"system":"sec-edgar","filing":"0000899243-19-013994","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/730272/000089924319013994/doc4.xml","form_type":"4"}},{"id":3929905,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2018-05-17T20:43:26.000Z","date":"2018-05-16","kind":"grant","acquired":true,"shares":3304,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Award vests in full one year from grant date on May 16, 2019."}],"balance_after":3304,"derivative":{"exercise_price":42.07,"exercise_date":"2019-05-16","expiration_date":"2028-05-16","underlying":"Common Stock","underlying_shares":3304},"source":{"system":"sec-edgar","filing":"0001140361-18-024448","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/730272/000114036118024448/doc1.xml","form_type":"4"}},{"id":3929904,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2018-05-17T20:43:26.000Z","date":"2018-05-16","kind":"grant","acquired":true,"shares":1486,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Mr. Cox was awarded 1,486 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The Restricted Stock Units vest on May 16, 2019. The Restricted Stock Units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance."}],"balance_after":6313,"source":{"system":"sec-edgar","filing":"0001140361-18-024448","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/730272/000114036118024448/doc1.xml","form_type":"4"}},{"id":4005604,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2018-03-08T16:47:09.000Z","date":"2018-03-08","kind":"disposition_to_issuer","acquired":false,"shares":193683,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."}],"balance_after":0,"derivative":{"exercise_price":44.51,"underlying":"Common Stock","underlying_shares":193683},"source":{"system":"sec-edgar","filing":"0001127602-18-010647","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760218010647/form4.xml","form_type":"4"}},{"id":4005603,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2018-03-08T16:47:09.000Z","date":"2018-03-08","kind":"disposition_to_issuer","acquired":false,"shares":387366,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."}],"balance_after":0,"derivative":{"exercise_price":44.51,"underlying":"Common Stock","underlying_shares":387366},"source":{"system":"sec-edgar","filing":"0001127602-18-010647","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760218010647/form4.xml","form_type":"4"}},{"id":4005602,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2018-03-08T16:47:09.000Z","date":"2018-03-08","kind":"disposition_to_issuer","acquired":false,"shares":48230,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Pursuant to the Merger Agreement, each option outstanding immediately prior to the consummation of the Offer, whether vested or unvested, automatically  became fully vested and was cancelled as of immediately prior to, and contingent upon, the consummation of the Offer in exchange for the right to receive a lump-sum cash payment in the amount of the Option Consideration, if any, less any required withholding taxes, with respect to such Option. \"Option Consideration\" means, with respect to any Option, an amount equal to the product of (i) the number of Shares issuable under such Option multiplied by (ii) the excess of (x) $105.00 over (y) the exercise price payable in respect of each Share issuable under such Option."}],"balance_after":0,"derivative":{"exercise_price":7.82,"underlying":"Common Stock","underlying_shares":48230},"source":{"system":"sec-edgar","filing":"0001127602-18-010647","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760218010647/form4.xml","form_type":"4"}},{"id":4005601,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2018-03-08T16:47:09.000Z","date":"2018-03-08","kind":"disposition_to_issuer","acquired":false,"shares":48678,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one Share of the issuer's common stock."},{"field":"shares","element":"transactionShares","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":48678},"source":{"system":"sec-edgar","filing":"0001127602-18-010647","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760218010647/form4.xml","form_type":"4"}},{"id":4005600,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2018-03-08T16:47:09.000Z","date":"2018-03-08","kind":"disposition_to_issuer","acquired":false,"shares":136364,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one Share of the issuer's common stock."},{"field":"shares","element":"transactionShares","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Pursuant to the Merger Agreement, each RSU outstanding immediately prior to the consummation of the tender offer by Parent and Merger Sub to acquire all the outstanding Shares for $105.00 in cash (the \"Offer\") automatically and without any required action on the part of its holder became fully vested and was converted immediately prior to, and contingent upon, the consummation of the Offer into a vested right to receive a lump-sum payment in an amount equal to $105.00 for each Share underlying the RSU, less any required withholding taxes."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":136364},"source":{"system":"sec-edgar","filing":"0001127602-18-010647","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760218010647/form4.xml","form_type":"4"}},{"id":4005599,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-03-08T16:47:09.000Z","date":"2018-03-08","kind":"disposition_to_issuer","acquired":false,"shares":185094,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes 67,780 shares subject to restricted stock units.  See also note 4."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the Agreement and Plan of Merger, dated as of January 21, 2018 (the \"Merger Agreement\"), between the Company, Sanofi, a French soci?t? anonyme (the \"Parent\"), and Blink Acquisition Corp. (\"Merger Sub\"), on March 8, 2018, Merger Sub was merged with and into the Company, with the Company continuing as the surviving corporation and a wholly owned subsidiary of Parent (the \"Merger\").  Pursuant to the Merger Agreement, at the effective time of the Merger, each share of common stock, par value $0.001 per share, of the Company (each, a \"Share\") was converted into the right to receive $105.00 in cash."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001127602-18-010647","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760218010647/form4.xml","form_type":"4"}},{"id":4033886,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-02-26T22:11:28.000Z","date":"2018-02-23","kind":"tax_withholding","acquired":false,"shares":5794,"price":104.74,"value":606863.56,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":185094,"source":{"system":"sec-edgar","filing":"0001127602-18-008443","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760218008443/form4.xml","form_type":"4"}},{"id":4033885,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-02-26T22:11:28.000Z","date":"2018-02-22","kind":"tax_withholding","acquired":false,"shares":13973,"price":104.3,"value":1457383.9,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":190888,"source":{"system":"sec-edgar","filing":"0001127602-18-008443","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760218008443/form4.xml","form_type":"4"}},{"id":4054879,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2018-02-15T22:04:51.000Z","date":"2018-02-14","kind":"exercise","acquired":false,"shares":24339,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The restricted stock units vest in three equal annual installments beginning on February 14, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The restricted stock units vest in three equal annual installments beginning on February 14, 2018."}],"balance_after":48678,"derivative":{"underlying":"Common Stock","underlying_shares":24339},"source":{"system":"sec-edgar","filing":"0001127602-18-006418","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760218006418/form4.xml","form_type":"4"}},{"id":4054878,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-02-15T22:04:51.000Z","date":"2018-02-14","kind":"tax_withholding","acquired":false,"shares":10819,"price":103.52,"value":1119982.88,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":204861,"source":{"system":"sec-edgar","filing":"0001127602-18-006418","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760218006418/form4.xml","form_type":"4"}},{"id":4054877,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-02-15T22:04:51.000Z","date":"2018-02-14","kind":"exercise","acquired":true,"shares":24339,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":215680,"source":{"system":"sec-edgar","filing":"0001127602-18-006418","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760218006418/form4.xml","form_type":"4"}},{"id":4062869,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2018-02-13T22:01:50.000Z","date":"2018-02-11","kind":"exercise","acquired":false,"shares":18381,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents stock options to purchase Bioverativ common stock granted to the reporting person as a result of the conversion of existing Biogen stock options held by the reporting person prior to the spin-off of Bioverativ from Biogen on February 1, 2017, as set forth in an employee matters agreement entered into between Bioverativ and Biogen in connection with the spin-off.  These stock options are subject to the terms of the Bioverativ 2017 Omnibus Equity Plan.  Under the terms of the Bioverativ 2017 Omnibus Equity Plan, vested stock options are automatically exercised if on the expiration date of such stock option the per share exercise price is less than the closing price of the common stock on that date.  Further, under the 2017 Omnibus Equity Plan, after such exercise, the Company will deliver to the reporting person that number of shares subject to the vested stock option less the number of shares with a value that is equal to the aggregate fair market value of (1) the aggregate exercise price of the vested stock option and (2) the amount necessary to satisfy any required withholding of taxes or social insurance contributions."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option is presently exercisable in full."}],"balance_after":0,"derivative":{"exercise_price":9.53,"expiration_date":"2018-02-11","underlying":"Common Stock","underlying_shares":18381},"source":{"system":"sec-edgar","filing":"0001127602-18-005561","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760218005561/form4.xml","form_type":"4"}},{"id":4062868,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-02-13T22:01:50.000Z","date":"2018-02-11","kind":"tax_withholding","acquired":false,"shares":7672,"price":103.05,"value":790599.6,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares withheld by Bioverativ upon the automatic exercise of stock options to satisfy the aggregate exercise price and required tax withholdings."}],"balance_after":191341,"source":{"system":"sec-edgar","filing":"0001127602-18-005561","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760218005561/form4.xml","form_type":"4"}},{"id":4062867,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2018-02-13T22:01:50.000Z","date":"2018-02-11","kind":"exercise","acquired":true,"shares":18381,"price":9.53,"value":175170.93,"ownership":{"direct":true},"balance_after":199013,"source":{"system":"sec-edgar","filing":"0001127602-18-005561","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760218005561/form4.xml","form_type":"4"}},{"id":4079229,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2018-02-02T22:07:57.000Z","date":"2018-01-31","kind":"grant","acquired":true,"shares":136364,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest in three equal annual installments beginning on January 31, 2019."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest in three equal annual installments beginning on January 31, 2019."}],"balance_after":136364,"derivative":{"underlying":"Common Stock","underlying_shares":136364},"source":{"system":"sec-edgar","filing":"0001127602-18-003801","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760218003801/form4.xml","form_type":"4"}},{"id":4311072,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2017-05-22T21:01:08.000Z","date":"2017-05-18","kind":"grant","acquired":true,"shares":2434,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Award vests in full one year from grant date on May 18, 2018."}],"balance_after":2434,"derivative":{"exercise_price":38.76,"exercise_date":"2018-05-18","expiration_date":"2027-05-18","underlying":"Common Stock","underlying_shares":2434},"source":{"system":"sec-edgar","filing":"0001140361-17-021758","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/730272/000114036117021758/doc1.xml","form_type":"4"}},{"id":4311071,"issuer":{"id":486,"kind":"organization","name":"REPLIGEN CORP","symbol":"RGEN"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2017-05-22T21:01:08.000Z","date":"2017-05-18","kind":"grant","acquired":true,"shares":1206,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Mr. Cox was awarded 1,206 Restricted Stock Units. Each Restricted Stock Unit represents a contingent right to receive one share of Repligen Corporation's Common Stock. The Restricted Stock Units vest on May 18, 2018. The Restricted Stock Units may be settled only by delivering shares of Repligen Corporation's Common Stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance."}],"balance_after":4827,"source":{"system":"sec-edgar","filing":"0001140361-17-021758","document":"doc1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/730272/000114036117021758/doc1.xml","form_type":"4"}},{"id":4365205,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-04-03T20:16:50.000Z","date":"2017-03-31","kind":"tax_withholding","acquired":false,"shares":8416,"price":54.46,"value":458335.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":180632,"source":{"system":"sec-edgar","filing":"0001127602-17-013535","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760217013535/form4.xml","form_type":"4"}},{"id":4371522,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2017-03-27T20:27:53.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":387366,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests in full on the third anniversary of the date of grant."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing."}],"balance_after":387366,"derivative":{"exercise_price":44.51,"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":387366},"source":{"system":"sec-edgar","filing":"0001127602-17-012948","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760217012948/form4a.xml","form_type":"4/A","original_submission_date":"2017-02-16"}},{"id":4371521,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2017-03-27T20:27:53.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":193683,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option vests in three equal annual installments beginning on February 14, 2018."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"The number of derivative securities acquired, the amount or number of shares and the number of derivative securities beneficially owned following the reported transaction have been amended from the original filing."}],"balance_after":193683,"derivative":{"exercise_price":44.51,"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":193683},"source":{"system":"sec-edgar","filing":"0001127602-17-012948","document":"form4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760217012948/form4a.xml","form_type":"4/A","original_submission_date":"2017-02-16"}},{"id":4409753,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2017-03-02T21:08:45.000Z","date":"2017-02-28","kind":"grant","acquired":true,"shares":18381,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents stock options to purchase Bioverativ common stock granted to the reporting person as a result of the conversion of existing Biogen stock options held by the reporting person prior to the Spin-Off, as set forth in an employee matters agreement entered into between Bioverativ and Biogen in connection with the Spin-Off."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is presently exercisable in full."}],"balance_after":18381,"derivative":{"exercise_price":9.53,"expiration_date":"2018-02-11","underlying":"Common Stock","underlying_shares":18381},"source":{"system":"sec-edgar","filing":"0001127602-17-009673","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760217009673/form4.xml","form_type":"4"}},{"id":4409752,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2017-03-02T21:08:45.000Z","date":"2017-02-28","kind":"grant","acquired":true,"shares":48230,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"Represents stock options to purchase Bioverativ common stock granted to the reporting person as a result of the conversion of existing Biogen stock options held by the reporting person prior to the Spin-Off, as set forth in an employee matters agreement entered into between Bioverativ and Biogen in connection with the Spin-Off."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"This option is presently exercisable in full."}],"balance_after":48230,"derivative":{"exercise_price":7.82,"expiration_date":"2019-02-23","underlying":"Common Stock","underlying_shares":48230},"source":{"system":"sec-edgar","filing":"0001127602-17-009673","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760217009673/form4.xml","form_type":"4"}},{"id":4409751,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-03-02T21:08:45.000Z","date":"2017-02-28","kind":"tax_withholding","acquired":false,"shares":6726,"price":43.42,"value":292042.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":189048,"source":{"system":"sec-edgar","filing":"0001127602-17-009673","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760217009673/form4.xml","form_type":"4"}},{"id":4409750,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-03-02T21:08:45.000Z","date":"2017-02-28","kind":"tax_withholding","acquired":false,"shares":6436,"price":47.76,"value":307383.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":195774,"source":{"system":"sec-edgar","filing":"0001127602-17-009673","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760217009673/form4.xml","form_type":"4"}},{"id":4409749,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-03-02T21:08:45.000Z","date":"2017-02-28","kind":"tax_withholding","acquired":false,"shares":2641,"price":49.56,"value":130887.96,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":202210,"source":{"system":"sec-edgar","filing":"0001127602-17-009673","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760217009673/form4.xml","form_type":"4"}},{"id":4409748,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-03-02T21:08:45.000Z","date":"2017-02-28","kind":"tax_withholding","acquired":false,"shares":6986,"price":43.42,"value":303332.12,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":204851,"source":{"system":"sec-edgar","filing":"0001127602-17-009673","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760217009673/form4.xml","form_type":"4"}},{"id":4409747,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-03-02T21:08:45.000Z","date":"2017-02-28","kind":"tax_withholding","acquired":false,"shares":8355,"price":47.76,"value":399034.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":211837,"source":{"system":"sec-edgar","filing":"0001127602-17-009673","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760217009673/form4.xml","form_type":"4"}},{"id":4409746,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-03-02T21:08:45.000Z","date":"2017-02-28","kind":"tax_withholding","acquired":false,"shares":3383,"price":49.56,"value":167661.48,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":220192,"source":{"system":"sec-edgar","filing":"0001127602-17-009673","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760217009673/form4.xml","form_type":"4"}},{"id":4409745,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-03-02T21:08:45.000Z","date":"2017-02-28","kind":"tax_withholding","acquired":false,"shares":3404,"price":43.42,"value":147801.68,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents the number of shares forfeited by the reporting person to cover the payment of taxes incurred as a result of vesting of restricted stock units."}],"balance_after":223575,"source":{"system":"sec-edgar","filing":"0001127602-17-009673","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760217009673/form4.xml","form_type":"4"}},{"id":4409744,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2017-03-02T21:08:45.000Z","date":"2017-02-28","kind":"grant","acquired":true,"shares":211679,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Includes restricted stock units granted by Bioverativ Inc. (\"Bioverativ\") to the reporting person as a result of the conversion of existing Biogen Inc. (\"Biogen\") cash-settled performance units, market stock units and restricted stock units held by the reporting person prior to the spin-off of Bioverativ from Biogen on February 1, 2017 (\"Spin-off\"), as set forth in an employee matters agreement entered into between Bioverativ and Biogen in connection with the Spin-Off.  Restricted stock units that are unvested continue to vest on the dates of the original Biogen awards."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 15,300 shares acquired in a pro rata distribution by Biogen in connection with the Spin-Off."}],"balance_after":226979,"source":{"system":"sec-edgar","filing":"0001127602-17-009673","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760217009673/form4.xml","form_type":"4"}},{"id":4442632,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2017-02-16T21:38:44.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":386675,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This option vests in full on the third anniversary of the date of grant."}],"balance_after":386675,"derivative":{"exercise_price":44.51,"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":386675},"source":{"system":"sec-edgar","filing":"0001127602-17-006616","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760217006616/form4.xml","form_type":"4"}},{"id":4442631,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Non-Qualified Stock Option","published_at":"2017-02-16T21:38:44.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":193337,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests in three equal annual installments beginning on February 14, 2018."}],"balance_after":193337,"derivative":{"exercise_price":44.51,"expiration_date":"2027-02-14","underlying":"Common Stock","underlying_shares":193337},"source":{"system":"sec-edgar","filing":"0001127602-17-006616","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760217006616/form4.xml","form_type":"4"}},{"id":4442630,"issuer":{"id":168487,"kind":"organization","name":"Bioverativ Inc.","symbol":"BIVV"},"owners":[{"id":22907,"kind":"person","name":"Cox John","position":1,"cik":"0001498428","reported_name":"Cox John","relationship":{"director":true,"officer":true,"officer_title":"Chief Executive Officer"}}],"security":"Restricted Stock Units","published_at":"2017-02-16T21:38:44.000Z","date":"2017-02-14","kind":"grant","acquired":true,"shares":73017,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The restricted stock units vest in three equal annual installments beginning on February 14, 2018."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The restricted stock units vest in three equal annual installments beginning on February 14, 2018."}],"balance_after":73017,"derivative":{"underlying":"Common Stock","underlying_shares":73017},"source":{"system":"sec-edgar","filing":"0001127602-17-006616","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1498428/000112760217006616/form4.xml","form_type":"4"}}]}